David Prado
Psychiatry · Philadelphia, PANPI 1073946919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,233 and has fallen 92.2% since, to $96 in 2024.
Across 209 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$681
- Otsuka America Pharmaceutical, Inc.$529
- AbbVie$466
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$361
- Supernus Pharmaceuticals, Inc.$337
- Lundbeck LLC$253
- plus $959 from 10 others
What the payments were for
- Food & beverage$3,47297%
- Education$1143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 36 | $681 |
| Otsuka America Pharmaceutical, Inc. | 33 | $529 |
| AbbVie(2 entities) | 34 | $466 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $361 |
| Supernus Pharmaceuticals, Inc. | 15 | $337 |
| Lundbeck LLC | 14 | $253 |
| Sunovion Pharmaceuticals Inc. | 16 | $214 |
| Neurocrine Biosciences, Inc. | 13 | $209 |
| Johnson & Johnson | 7 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Ironshore Pharmaceuticals Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Shire North American Group Inc | 3 | $54 |
| Indivior Inc. | 2 | $31 |
| Tris Pharma Inc | 1 | $15 |
How this compares
$3,586 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 11 | $4,879 |
| Aripiprazole | 16 | $1,084 |
| Risperidone | 29 | $383 |
| Duloxetine Hcl | 19 | $212 |
| Trazodone Hcl | 30 | $179 |
| Quetiapine Fumarate | 15 | $111 |
| Sertraline Hcl | 12 | $100 |
| Fluoxetine Hcl | 12 | $86 |
| Clonazepam | 11 | $82 |
| Lorazepam | 19 | $73 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.